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Bone marrow transplantation (BMT) to treat severe hematologic malignancies often leads to potentially fatal
acute graft-versus-host disease (GVHD), despite attempts at better donorerecipient matching and/or use of
immunosuppressive agents. We report that embryo-derived PreImplantation Factor (PIF) plays a determining
role in developing maternal/host tolerance toward the semiallogeneic or total allogeneic embryo and in
regulating systemic immune response. Synthetic PIF treatment has proven effective in preventing immune
attacks in nonpregnant models of autoimmunity. In this study, we tested the capability of PIF to prevent the
development of acute GVHD in semiallogeneic or totally allogeneic murine BMT models. We examined the
regulatory effect of PIF both in vivo and in vitro to control deleterious GVHD while maintaining its ability to
preserve the beneﬁcial graft-versus-leukemia (GVL) effect. Bone marrow and spleen cells from C57BL/6
donors were transplanted in semiallogeneic (C57BL/6xBALB/c) F1 or allogeneic (BALB/c) mice, which were
then treated with PIF 1 mg/kg/day for 2 weeks. Short-term PIF administration reduced acute GVHD in both
models and increased survival for up to 4 months after semiallogeneic or totally allogeneic BMT. This effect
was coupled with decreased skin inﬂammation (semiallogeneic model) and decreased liver inﬂammation
(both models), as well as reduced colon ulceration (allogeneic model). GVHD-associated cytokine and che-
mokine gene expression were decreased in the liver. PIF further lowered circulating IL-17 levels, but not IFN-g
levels. Both in vivo and in vitro, PIF treatment was demonstrated to lead to decreased inducible nitric oxide
synthase expression and decreased lipopolysaccharide-activated macrophages to lower nitric oxide secretion.
Signiﬁcantly, PIF did not diminish the beneﬁcial GVL effect in the B cell leukemia model. PIF acts primarily by
inducing the regulatory phenotype on monocytes/antigen-presenting cells, which controls T cell proliferation.
Overall, our data demonstrate that PIF protects against semiallogeneic and allogeneic GVHD long term by
reducing both target organ and systemic inﬂammation and by decreasing oxidative stress, while preserving
the beneﬁcial GVL effect.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION Acute GVHD is characterized by widespread damage,
Allogenic bone marrow transplantation (BMT), per-
formed in thousands of patients each year, is a well-
established treatment modality for malignant and
nonmalignant hematologic diseases. Within this type of
stem cell graft, mature donor T cells are the main mediators
of the beneﬁcial induction of the beneﬁcial graft-versus-
leukemia (GVL) effect that prevents relapse of malignancy
[1,2]. Unfortunately, these same cells also induce graft-
versus-host disease (GVHD), a major cause of morbidity
and mortality in BMT recipients [3]. Recent studies suggest
the involvement of the inﬂammatory Th1 response as well as
Th17 cells in autoimmunity [4,5].dgments on page 528.
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12.12.011affecting mainly target organs, such as the skin, liver, and
gastrointestinal tract [6]. Protecting these vital organs and
preventing the return of malignancy after immunosuppres-
sive drug administration remain difﬁcult clinical challenges.
Treating GVHD also poses serious challenges. Standard
GVHD prophylaxis and therapy involve the use of drugs that
cause generalized immune suppression, placing patients in
danger of opportunistic infections and tumor relapse [2]. The
initial management of acute GVHD usually includes steroids
in combination with other immunosuppressive agents;
however, this treatment is not effective in all patients [3].
Steroid-resistant GVHD may result in death [7]. Additional
agents have been evaluated for treating and preventing
GVHD [8], but none is currently in clinical use.
The ideal GVHD prophylaxis would exert 2 effects simul-
taneously: (1) prevent the grafted bone marrow cells from
attacking their new host, and (2) sustain and maintain the
new marrow’s ability to destroy the host’s remaining cancerTransplantation.
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pregnancy, which we characterize as both a perfect immune
regulatory environment and a successful transplantation
model. The host/mother’s immune system accepts a semi-
allogeneic embryo (or a totally allogeneic one, in the case of
a donor embryo) successfully. In pregnancies associated with
infection or immune disorders, embryo tolerance continues
to be preserved while maternal ability to ﬁght disease is not
only not impaired but may even become heightened, as
needed. Pregnancy is an immune tolerant state, not an
immunosuppressed state, in which the embryo/graft and
mother/host synergize for best results. A number of mecha-
nisms are involved in this feto-maternal tolerance. Some of
these include modulated/regulatory immune cells, such as
M2 macrophages and uterine natural killer (NK) cells [9,10].
Thus, the immunologic proﬁle of pregnancy is compatible
with that of the desired GVHD prophylaxis [11-14].
Our research found that PreImplantation Factor (PIF),
an evolutionary conserved embryo-derived peptide
(MVRIKPGSANKPSDD), is expressed by the embryo/fetus and
placenta and present in the maternal circulation of viable
pregnancies [15-20]. Our group demonstrated that synthetic
PIF modulates decidual immunity [21,22], reduces NK cell
toxicity, and promotes trophoblast invasion, which is
required for successful fetal development [23]. It also has
been demonstrated that PIF’s global immune regulatory
properties play an essential role in mediating pregnancy’s
unique immune milieu, allowing maintained defenses
against pathogens and disease [20]. We reported that PIF
orchestrates global anti-inﬂammatory effects in human
peripheral blood mononuclear cells. PIF binds naive CD14þ
cells (monocytes/leukocytes), and in activated peripheral
blood T cells and B cells, it blocks mixed lymphocyte reaction
(MLR) proliferation and leads to a Th2 cytokine bias while
preserving the Th1-type response. This was evidenced by the
effect of secretion and conﬁrmed by gene expression [24].
We also reported that low-dose PIF is effective in reducing
NK cell toxicity by reducing critical CD69 expression [25].
In nonpregnant mice, we have demonstrated that PIF
reverses paralysis and blocks spinal cord inﬂammationwhile
promoting neural repair (chronic experimental autoimmune
encephalomyelitis model) [26-28]. PIF also was shown to
prevent autoimmune diabetes while restoring pancreatic
function and insulin expression (nonobese diabetic model)
[28]. In bothmodels, PIF acts by reducing oxidative stress and
inhibiting proinﬂammatory cytokine expression [26,28].
In the present study, we investigated the ability of PIF
administration to prevent alloactivation and acute GVHD in
a murine BMT model [29]. We examined PIF-induced protec-
tion by evaluating proinﬂammatory protein expression in
GVHD-affected tissues, as well as relevant circulating cytokine
levels. We assessed the effect of PIF on maintaining the
important beneﬁcial GVL effect. Finally, we identiﬁed the
mechanisms involved inPIF-inducedprotectionusing cultured
immunecells.Wereport that short-term, low-dosePIFprotects
against the development of acute GVHD while diminishing
proinﬂammatory mediators. PIF-protective effects are exerted
through monocytes, in which the reduced inducible nitric
oxide synthase (iNOS) expression decreases nitric oxide (NO)
secretion, thereby protecting against oxidative stress.METHODS
Animals
Female 8- to 11-week-old C57BL/6, BALB/c, and (C57BL/6xBALB/c) F1
mice were obtained from Harlan Laboratories (Jerusalem, Israel). The studywas conducted under appropriate conditions and was approved by the
Institutional Animal Care and Use Committee of the Hebrew University of
Jerusalem in accordance with national laws and regulations for the
protection of animals.
BMT
Recipient (C57BL/6xBALB/c) F1, BALB/c, or C57BL/6 mice received lethal
whole-body irradiation with a single dose of 1000 rad (semiallogeneic and
autologous) or 800 rad (allogeneic), and were reconstituted with 8  106
donor C57BL/6 bone marrow cells and 1.2  107 (semiallogeneic and
autologous) or 2  106 (allogeneic) spleen cells administered to the tail vein
on the following day. Bone marrow from donor mice was collected by
ﬂushing of the femur, humerus, and tibia into Dulbecco’s PBS (Biological
Industries, Kibutz Beit Haemek, Israel). Spleens were crushed through
70-mm screens into PBS. Bone marrow mononuclear cells and splenocytes
were isolated after centrifugation on a Ficoll-Paque gradient. Percent BMT
chimerism was measured in blood samples obtained 10 days after trans-
plantation by ﬂuorescent-activated cell sorting (FACS) analysis.
Peptide Synthesis
Synthetic PIF (MVRIKPGSANKPSDD) and scrambled PIF peptide (PIFscr)
(GRVDPSNKSMPKDIA) as a control were obtained by solid-phase peptide
synthesis (Peptide Synthesizer; Applied Biosystems, Foster City, CA) using
9-ﬂuorenylmethoxycarbonyl chemistry. FITC-labeled PIF (FITC-PIF) and
PIFscr (FITC-PIFscr) were produced by adding FITC on the N-terminus of PIF
in the solid phase using L-alanine as a spacer. Final puriﬁcation was per-
formed by reversed-phase HPLC, and peptide identity was veriﬁed by
matrix-assisted laser desorption/ionizationetime of ﬂight mass spectrom-
etry and amino acid analysis, puriﬁed to>95% by HPLC, and documented by
mass spectrometry at Bio-Synthesis (Lewisville, TX).
PIF Administration
PIF or PIFscr was dissolved in PBS. Solvent peptide or PBS alone (as
a control) was administered PIF (1 mg/kg/day) to the experimental groups
on the day of BMT, using ALZET osmotic pumps (model 1002; Durect,
Cupertino, CA), implanted s.c., slightly posterior to the scapulae. The pumps
provided a continuous infusion (0.25 mL/h) for up to 14 days. Mice were
followed up to 4 months without further therapy.
GVHD Evaluation
Mice were monitored daily for weight loss, diarrhea, rufﬂed skin, and
survival, as described previously [29]. GVHD disease score, based on all of
the foregoing factors (rated on a scale of 0-6), was calculated [6]. In addition,
peripheral blood samples were collected from the tail vein at day 18
post-BMT.
Histological Analysis
Representative liver, skin, spleen, and colon samples were obtained
from sacriﬁced mice and ﬁxed in 10% neutral-buffered formalin. Samples
were then embedded in parafﬁn, cut into 10-mm-thick sections, and stained
with hematoxylin and eosin. The sections were examined under an optical
microscope (CK40; Olympus, Tokyo, Japan), and images were captured with
an Olympus DP50 camera. The histopathological score of the liver was based
on the extent of leukocyte inﬁltration into the tissue. The histopathological
score of the skin was determined by evaluation of epidermal interface
changes, hair loss, and scar formation. The histopathological score of the
spleen in the GVL model was based on the degree of leukemic cell inﬁltra-
tion to the tissue. The histopathological score of the colon was based on the
degree of edema, crypt loss, crypt hyperplasia, and epithelial ulceration.
Serum Cytokine Evaluation
Mouse serum was obtained from peripheral blood. IL-17 levels were
measured by ELISA (Mouse IL-17A ELISA MAX; BioLegend, San Diego, CA).
IFN-g and IL-4 levels were also measured by ELISA (eBioscience, Hatﬁeld,
UK).
RNA Expression Analysis
Liver and gut samples were obtained from mice at 45 days after semi-
allogeneic, allogeneic, or autologous BMT and preserved in RNA Save (Bio-
logical Industries, Kibbutz Beit Haemek, Israel). RNAwas extracted using the
TRIzol reagent protocol (Invitrogen, Carlsbad, CA). DNA was removed from
the samples using an RNeasy column and on-column treatment with RNase-
free DNAse (Qiagen, Valencia, CA). cDNAwas synthesized from 0.5 mg of total
mouse liver RNA using the RT2 First-Strand Kit (SA Biosciences, Frederick,
MD), as reported previously [21]. Liver cDNAwas applied to a 96-well mouse
inﬂammatory response and autoimmunity microassay plate, and quantita-
tive PCR (SA Biosciences) was performed using a DNA Engine Opticon
Y. Azar et al. / Biol Blood Marrow Transplant 19 (2013) 519e528 5212 Thermocycler (Bio-Rad, Hercules, CA) with the following program: 95C
for 10 minutes, followed by 40 cycles of 95C for 15 seconds, 55C for
40 seconds, and 72C for 30 seconds. Data analysis was performed using the
SA Biosciences Web-Based PCR Array data analysis software.
GVL Effect Evaluation
After semiallogeneic BMT, F1 mice were inoculated with B cell leuke-
mia/lymphoma 1 (BCL1) cells. Osmotic pumps dispensing PIF (1 mg/kg/day)
or PBS (control) were implanted s.c. and left in place for 14 days. In the
control group, F1 mice underwent transplantation with syngenic cells, fol-
lowed by inoculation with BCL1 cells. For the survival assay, 2  104 BCL1
cells were used, and mice were followed up to day 16. At that point, the
surviving mice were sacriﬁced, and DNA was extracted from their spleen
cells and tested by PCR using BCL1 primers. In the splenomegaly assay,
1  104 BCL1 leukemia cells were used, and mice were followed for up to
18 days, with daily monitoring. On day 18 after BMT, the mice were sacri-
ﬁced, their spleens were removed and weighed, and histological analysis
was performed to conﬁrm leukemic development.
In Vitro Proliferation Experiments
MLR was performed as described previously [30] using irradiated
C57Bl/6 mouse splenocytes as stimulators and BALB/c mouse splenocytes as
responder cells. PIF was added to the culture medium as indicated. For
coculture experiments, monocytes were differentiated from whole bone
marrow of C57Bl/6 mice in a medium supplemented with granulocyte
macrophage colony-stimulating factor (GM-CSF) for 10 days as described
previously [31], in the presence or absence of 200 nM PIF. Subsequently,
8 103 monocytes were cultured with 4105 T cells for 4 days, activated by
anti-CD3 antibody (BioLegend). H3 thymidine was added to the culture
during the last 18 hours of incubation. Cells were harvested onto glass-ﬁber
ﬁlters, and H3 thymidine incorporation was measured by liquid scintillation
using a TopCount NXT analyzer (PerkinElmer, Waltham, MA).
Flow Cytometry Analysis
Bone marrow cells were collected by ﬂushing of the femurs and tibias of
C57Bl/6mice. Blood cells were obtained from tails. Cellswere incubatedwith
3.1 mM FITC-PIF (bone marrow) or 6.2 mM FITC-PIF (blood) or with the same
concentrations of FITC-PIFscr conjugates (control) for 15 minutes before
a 1-hour incubation with antibodies against markers for immune cell pop-
ulations: anti-CD3 PE (eBioscience), anti-CD19 antigen-presenting cells
(APCs; BD Biosciences, San Jose, CA) and anti-CD11b APCs (SouthernBiotech,
Birmingham, AL). Chimerismwas assessed using anti-H2d antibodies. B7-H1
expression was tested on CD11b cells differentiated with GM-CSF in the
medium for 10 days in the presence of 200 nM PIF in culture. INF-g was
added during in the last 24 hours, and anti-mouse B7-H1 PE antibodies
(eBioscience) were used for FACS analysis. Flow cytometry was performed
with aMACSQuant analyzer (Miltenyi Biotech, Bergisch Gladbach, Germany).
Nitrite Measurement and iNOS Quantitative PCR Analysis
RAW cells were cultured in DMEM medium for 4-5 days. PIF (200 nM)
was added to the culture at day 0 and/or day 3 of the experiment. For cell
activation, lipopolysaccharide (LPS) was added for the last 24 hours of the
experiment. Nitrite accumulation, an indicator of NO production, was
measured in cell culture supernatants using Griess reagent (a mixture at 1:1
of 0.1% naphthylethylenediamine dihydrochloride and 1% sulfanilamide in
3% H3PO4; Sigma-Aldrich, St Louis, MO). The supernatants (100 mL) were
mixed with an equal volume of Griess reagent, and absorbance at 550 nm
was measured in a microplate reader. The nitrite concentration was calcu-
lated from an NaNO2 standard curve.
Quantitative PCR
Detection of transcript levels of the iNOS gene in cDNA from PIF-treated
RAW cells and PIF-treated tissues frommice that underwent allogeneic BMT
(liver and colon) was performed using the TaqMan Gene Expression Assay
Kit (Applied Biosystems). Mouse HPRT-1 was used as a housekeeping gene
transcript. Primers and probes were purchased from Syntezza Bioscience
(Jerusalem, Israel). Data analysis was done using StepOne version 2.2
(Applied Biosystems). Each sample was analyzed in triplicate.
Statistical Analysis
GVHD and GVL data from the mouse experiments were analyzed using
the Student t test or c2 test. Histological data were analyzed using the
nonparametric Mann-Whitney U test. Gene expression and serum cytokine
levels were analyzed using the Student t test. In vitro data were analyzed
using the Student t, c2, or Mann-Whitney U test. Signiﬁcance was set at
P < .05.RESULTS
PIF Protects against GVHD and Improves Survival after
Semiallogeneic BMT
To test the prophylactic effect of PIF on GVHD, F1
(C57BL/6xBALB/c) mice underwent whole-body irradiation
followed by semiallogeneic BMT from donor C57BL/6 mice.
PIF (1 mg/kg/day) or PBS (control) was administered for 2
weeks via an s.c.-implanted continuous-release osmotic
pump, starting on the day of BMT. GVHD disease scores
(based on skin lesions, diarrhea, and body weight, on a scale
of 0-6), were signiﬁcantly lower in the PIF-treated mice than
in PBS-treated controls at 4 and 6 weeks post-BMT
(Figure 1A). The overall improved clinical condition of the
PIF-treated mice was reﬂected by signiﬁcant body weight
recovery (Figure 1B) and improved survival (Figure 1C). All
mice experienced weight loss after irradiation therapy and
recovered atw18 days post-BMT. In contrast to controls, the
PIF-treated mice continued to gain weight, and 88% of them
survived to the end of the experiment. PIF administration had
no effect on mice chimerism, which was >96% (Figure S1).
To determine the speciﬁcity of PIF’s activity, its anti-GVHD
effect was compared in the same model using scrambled
peptide (PIFscr) as control. PIFscr has the same amino acids
as PIF but in a different order. Mice were monitored for 4
months after transplantation to determine differences in the
effect of PIF and PIFscr on survival. In 2 independent exper-
iments, mice receiving PIFscr (1 mg/kg/day for 2 weeks)
exhibited no protective effects against acute GVHD. In
comparison, those receiving PIF showed signiﬁcant protec-
tion (Figure 1D and E). Notably, only 16% of the mice
receiving PIFscr survived for more than 100 days post-BMT,
compared with 91% of the PIF-treated mice. Furthermore,
although PIF was administered for only 2 weeks, its protec-
tive effect lasted for more than 100 days post-BMT
(Figure 1E). Our data conﬁrm short-term PIF-induced long-
term GVHD protection.
PIF Reduces Skin and Liver Inﬂammation
We examined the effect of PIF treatment on skin, liver,
and colon histopathology. In our semiallogeneic model,
GVHD affected mainly the skin and liver (Figure 2), and only
occasionally the colon (data not shown). At 45 days
post-BMT, mice were sacriﬁced, and biopsy specimens were
obtained from the 3 types of tissues. PIF-treated mice had
noticeably fewer and less-severe skin lesions (indicators of
GVHD) compared with control mice (Figure 2A). Histological
examination of skin biopsy specimens showed severe
ulcerations and rufﬂed skin in control mice, but not in the
mice receiving PIF. The differences in histopathological
scores were similarly signiﬁcant. Liver histology revealed
lymphocytic inﬁltrates in control mice, indicating a severe
inﬂammatory immune response, but not in PIF-treated mice
(Figure 2B). The differences in histopathological scores were
signiﬁcant here as well. These data document PIF-induced
protection of GVHD target organs.
PIF Down-Regulates GVHD-Associated Gene Expression in
the Liver and Circulating IL17 Levels
The decreased lymphocyte inﬁltration to the liver in
PIF-treated mice encouraged us to evaluate local inﬂamma-
tory gene expression, speciﬁcally chemokines, cytokines, and
their receptors. We used liver cDNA samples in a mouse
inﬂammatory response and autoimmunity microassay, with
analysis by quantitative PCR (qPCR). In PBS control-treated
mice, proinﬂammatory gene expression increased by
Figure 1. PIF reduces GVHD after semiallogeneic BMT. Mice underwent BMT with semiallogeneic bone marrow and spleen cells, and received PIF 1 mg/kg/day or PBS
via s.c.-implanted osmotic pumps for 2 weeks. (A) GVHD scores at 4 and 6 weeks post-BMT; summary of 4 experiments. The difference between the PBS-treated
control mice and the PIF-treated group is highly signiﬁcant (P  .0001 at 4 weeks and P  .004 at 6 weeks, t test). The line represents median score of each
group. (B) Weights from day 0 to day 45 post-BMT. The between-group difference is signiﬁcant starting at day 27 (P  .009, t test). (C) Survival of mice from day 0 to
day 45 post-BMT; summary of 2 experiments. Survival is signiﬁcantly higher in the PIF-treated group compared with the PBS group (*P  .04, c2 test). (D) GVHD score
at 4 weeks and 6 weeks post-BMT; summary of 2 experiments. Mice underwent transplantation as described and were treated with PIF or PIFscr 1 mg/kg/day via s.c.-
implanted osmotic pumps for 2 weeks. At 6 weeks, the difference between the PIFscr- and the PIF-treated groups is signiﬁcant (P  .004, t test). (E) Survival of mice
from day 0 to day 112 post-BMT; summary of 2 experiments. Survival is signiﬁcantly higher in the PIF-treated group compared with the PIFscr group (**P  .0004, c2
test).
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PIF-treated mice, only 20% of the proinﬂammatory genes
were elevated compared with naive mice (Figure 3A). More-
over, PIF treatment signiﬁcantly prevented up-regulation of
cytokines, chemokines, and associated receptors involved in
liver GVHD (Figure 3B and C; details in Figure S2). Geneswere
considered relevant to GVHD if their expressionwas elevated
in the semiallogeneic BMT liver but not in autologous BMT
liver. Interestingly, among the genes associated with liver
GVHD that were down-regulated by PIF, we found inducible
nitric oxide synthase (iNOS). The increased expression of this
gene in control mice liver was almost abolished in the
PIF-treated mice (Figure 3D; details in Figure S2).
Several of the GVHD up-regulated genes in the liver were
either Th1 or Th17 associated genes, immune pathways
known to be activated in GVHD. These results are related
mostly to inﬁltrating inﬂammatory cells in the liver. Thus,
PIF’s systemic effects were determined by evaluating circu-
lating levels of representative Th1, Th2, and Th17 type cyto-
kines (IFN-g, IL-4, and IL-17, respectively) in the serum of
BMT recipient mice at 3 weeks post-transplantation. Inter-
estingly, PIF-treated mice had markedly reduced serum
levels of IL-17, but not of IFN-g (Figure 3E). IL-4 levels
remained low in both groups (data not shown). The 2 groups
are PIF-treated and PBS.PIF Administration Does Not Interfere with the Beneﬁcial
GVL Effect
Based on our observation that PIF protects against the
development of GVHD, we tested whether its effects inter-
fere with the beneﬁcial GVL effect normally associated with
GVHD, using the BCL1 model [7]. This form of leukemia is
characterized by extreme splenomegaly and leads to death
in 100% of cases. We used spleen weight and survival to
evaluate the effect of PIL on GVL activity. Lower spleen
weight and increased survival would indicate a beneﬁcial
GVL effect.
We ﬁrst tested PIF administration on the survival of
post-BMT leukemic mice. Irradiated mice underwent semi-
allogeneic BMT as described above and were then inoculated
with a large dosage of BCL1 cells (2  104). Two test groups
were used: 1 group that received PIF 1 mg/kg/day for 2
weeks (BMT PIF group) and 1 group that received PBS for 2
weeks (BMT PBS group). A third group that underwent
autologous BMT and was then inoculated with BCL1 cells
served as a control group in which no GVL or GVHD effects
were expected. Survival at day 16 was similar in the BMT PIF
and BMT PBS groups, signiﬁcantly different from that in the
control group (Figure 4A). qPCR analysis on DNA extracted
from the spleen of the surviving animals was performed to
the ensure presence of cancerous cells in all mice.
Figure 2. PIF reduces skin ulceration and liver inﬂammation. (A) The upper
panels show representative pictures at 1 month post-BMT of a PBS-treated
control mouse, a PIF-treated mouse, and a normal control (C57BL/6BALB/c)
F1 mouse. *, indicates osmotic pump;A, GVHD skin ulcers. The lower panels
show representative histology of skin at 2 months post-BMT, along with
average histopathological scores. The differences in histopathological scores
are signiﬁcant (P  .02, Mann-Whitney U test). (B) Representative liver
histology at 2 months post-BMT and average histopathological scores.
Lymphocyte inﬁltration is denoted by an arrow. The differences in histo-
pathological scores are signiﬁcant (P  .03, Mann-Whitney U test).
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groups, as above) with fewer BCL1 cells (1  104) were
inoculated and sacriﬁced at 18 days post-BMT. Spleens were
weighted and subjected to histological analysis. Spleenweights were markedly lower in both the PIF and PBS groups
compared with the control group (Figure 4B), indicating the
presence of a GVL effect. Histological analysis demonstrated
the presence of leukemic cells in all mice, but the PIF and PBS
groups had lower disease burden and better spleen tissue
architecture compared with the control group (Figure 4C).
These data indicate PIF-induced protection against GVHD
coupled with the maintained GVL effect.
PIF is Equally Protective against GVHD in an Allogeneic
BMT Model
Most of our results were obtained using a semiallogeneic
BMT model (C57BL to C57BL/6xBALB/c F1). We also tested
whether PIF equally protects against GVHD in a more severe
model after full MHC mismatch, using a C57BL to BALB/c
allogeneic murine BMT model. In this model, GVHD affected
mostly the liver and colon. Similar to results for the semi-
allogeneic model, we noted a signiﬁcant reduction of GVHD
with PIF treatment (Figure 5). In addition to improved
disease scores (Figure 5A and B) and survival (Figure 5C),
improved histopathological scores for liver (data not shown)
and colon (Figure 5D) was evident. Histological analysis of
the colon showed that PIF signiﬁcantly reduced ulceration
(P ¼ .02; 4.7 degrees of freedom). Moreover, PIF reduced
GVHD-induced iNOS expression both signiﬁcantly in the liver
(Figure 5E, right) and at borderline signiﬁcance in the colon
(Figure 5E, left).
PIF Regulates Immune Response Primarily through
Monocytes
To gain insight into PIF’s effects on the immune response,
we examined whether PIF could also modulate allogeneic
activation in vitro. To do so, we added PIF at various
concentrations to an MLR of Balb/c and C57Bl mouse sple-
nocytes, and found that PIF exerted a dose-dependent
inhibitory effect on allogeneic proliferation (Figure 6A).
PIF is an embryo-derived peptide secreted at the
embryoematernal interface. In our model, it exhibits
systemic effects; thus, we posited that PIF might regulate
immune cell function. To establish which cells mediate the
effects of PIF, we ﬁrst used FITC-labeled PIF and PIFscr to
identify associations with various immune cell populations.
FITC-PIF avidly bound bone marrowederived monocytes
(CD11bþ cells), but exhibited low binding to T cells (CD2) and
B cells (CD19) (Figure 6B, upper). Similar results were ob-
tained with circulating monocytes (Figure 6B, lower). Given
that monocytes preferably interact with PIF, we examined
the effect of CD11bþ cells differentiated from bonemarrow in
the presence of PIF in a coculture with anti-CD3
antibodyeactivated T cells. We found that PIF-pretreated
monocytes signiﬁcantly inhibited activated T cell prolifera-
tion (Figure 6C).
PIF Reduces iNOS Activity and Induces Regulatory
Phenotype on Monocytes
Among the genes associated with liver GVHD that were
down-regulated by PIF (Figure 3), we found elevated
expression of the iNOS gene in control mice liver. The
increase was almost abolished in PIF-treated mice
(Figures 3D and 5D). PIF treatment was also associated with
reduced iNOS expression in the colon (Figure 5C). Because
iNOS can be synthesized by resident hepatic macrophages
(Kupffer cells) in response to LPS and proinﬂammatory
cytokines, as well as by other hepatic cells [32], we tested
in vitrowhether PIF would have the same inhibitory effect on
Figure 3. PIF down-regulates GVHD-associated gene expression in the liver. (A-D) qPCR analysis of inﬂammatory gene expression in the liver using a mouse
inﬂammatory response and autoimmunity array. cDNA samples were obtained from livers of normal mice or mice after semiallogeneic/autologous BMT, treated with
PIF or PBS as described in the text. n ¼ 3 for each group. (A) Percentage of genes out of 84 inﬂammatory genes tested that were up-regulated at least 3-fold compared
with their expression in normal mice. (B) Expression of cytokines and cytokine receptors involved in liver GVHD. Gusb is shown as a negative control. (C) Expression
of chemokine and chemokine receptors involved in liver GVHD. Hprt1 is shown as a negative control. (D) Expression of iNOS involved in liver GVHD. (E) Levels of
proinﬂammatory cytokines in the serum of mice after semiallogeneic BMT, treated with PIF or PBS as in Figure 1. Blood samples were collected from tail veins at day
18 post-BMT. IL-17 levels in the serum of PIF- and PBS-treated mice were measured by ELISA (*P  .02, t test), as were IFN-g levels in the serum of PIF- and PBS-treated
mice. The between-group difference is not signiﬁcant.
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iNOS expression was reduced, and NO secretion was signiﬁ-
cantly reduced, in the LPS-activated RAW mouse macro-
phage cell line (Figure 6D and E).
B7H1 are regulatory receptors on the surface of mono-
cytes. The expression of B7-H1 receptors on host APCs plays
a crucial role in GVHD regulation after BMT [33]. Our
results show that PIF signiﬁcantly up-regulates B7H1
receptor expression on bone marrowederived monocytes
(Figure 6F).
DISCUSSION
The BMT procedure to treat preexisting malignancy
involves the destruction of cancer cells via a harsh condi-
tioning procedure, that is, chemotherapy combined with
speciﬁc and nonspeciﬁc immune responses of transplanted
immune cells against the tumor, collectively known as the
GVL effect [1,7]. Unfortunately, the nonspeciﬁc immune
response that contributes to the desired GVL effect is also
responsible for inducing deleterious GVHD [8]. To improve
post-BMT prognosis, it is necessary to reduce GVHD without
eliminating the GVL effect.Pregnancy is a unique immune state, a “perfect trans-
plant” in which there is no host-versus-graft (mother-
versus-embryo) immune reaction, or, conversely,
graft-versus-host (embryo-versus-mother) reaction, despite
the semiallogeneity or total allogeneity of the fetus [9,14,34].
Moreover, pregnant women do not experience immune
suppression, as evidenced by their maintained, adaptive, and
strengthened as-needed ability to ﬁght cancer and immune
disorders (eg, leukemia, multiple sclerosis) [11,20]. We
previously reported that PIF, an embryo-derived peptide,
plays a determining role in creating this maternal immune
tolerance toward the embryo, as well as promoting implan-
tation [21,23]. In addition, PIF reverses paralysis while
promoting neural repair and regeneration, and prevents the
development of type 1 diabetes while preserving pancreatic
insulin expression [26,28].
Herein we report that short-term, low-dose PIF admin-
istration prevents acute GVHD in both semiallogeneic and
totally allogeneic BMT models, while maintaining the bene-
ﬁcial GVL effect. A low dose of PIF (1 mg/kg/day) adminis-
tered for only 2 weeks increased long-term survival in
a GVHD model and decreased GVHD-related symptoms
Figure 4. PIF does not interfere with the GVL effect. Mice were inoculated with BCL1 cells after semiallogeneic BMT and received PIF 1 mg/kg/day (PIF group) or PBS
(PBS group) via s.c.-implanted osmotic pumps for 14 days. In the control group, mice underwent BMT with autologous cells and were then inoculated with BCL1 cells
(BCL group). (A) Mouse survival at 16 days after BMT and inoculation of 2  104 BCL1 cells. The differences between the PBS and PIF groups and the BCL1 group are
signiﬁcant (PBS versus BCL1, **P  .001; PIF versus BCL1, **P  .003, c2 test). (B) Comparison of spleen size on day 18 after BMT and inoculation of 1 104 BCL1 cells.
The differences between the PBS and PIF groups and the BCL1 group are signiﬁcant (PBS versus BCL1, **P  .002; PIF versus BCL1, ***P  .0004). (C) Histological
analysis of the spleen on day 18 after BMT and inoculation of 1  104 BCL1 cells. The differences between the PBS and PIF groups and the BCL1 group are signiﬁcant
(PIF versus BCL1, *P  .002; PBS versus BCL1, **P < .0001, Mann-Whitney U test).
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after cessation of therapy. The selected dose is in the same
physiological range found in the serum of pregnant women.
Our model uses semiallogeneic BMT (C57BL to C57BL/
6 BALB/c F1) [26]. We chose this model because in humans,
transplantation from a haploidentical donor (parent to child)
is the ﬁnal option, and total mismatched donors are not yet
used. GVHD is less severe in this model compared with our
fully allogeneic model; however, long-term survival is poor
in the semiallogeneic BMT model as well (Figure 1D). We
have conﬁrmed that PIF induced signiﬁcant protective effects
against a more severe form of GVHD using the fully alloge-
neic model (Figure 5). PIF’s anti-GVHD effect is speciﬁc, and
could not be replicated by PIFscr administration with
a scrambled PIF peptide used as control.
PIF-treated mice maintained their weight and exhibited
visibly less skin ulceration and inﬂammatory immune cell
inﬁltration into the liver. In our semiallogeneic model, GVHD
in the gut appeared only sporadically and thus was not
examined further. In the allogeneic model, PIF reduced colon
ulceration. In contrast, control mice experienced GVHD with
expected weight loss, extensive skin ulceration, and liver
inﬂammation. Overall, our data suggest that PIF offers
measurable protection against damage in major clinical
disease target organs, the skin, liver, and gut.To provide mechanistic insight into the PIF-induced
protection in the GVHD model, we performed several
complementary analyses, including gene expression and
circulating cytokine levels. We demonstrated that PIF blocks
up-regulation of several proinﬂammatory genes in the livers
of mice that underwent BMT, including cytokines, chemo-
kines, and their receptors. Decreased expression of IFN-g,
IL8r, and TNF-a genes, which are associated with Th1
response and inﬂammation, was documented. Although we
did not directly assess IL-17 expression in the liver, we found
elevated expression of IL-6 and IL-23a, which are important
for Th17 cell differentiation and proliferation. In addition,
IL-23R, CCR4, TNF-a, IL-22, and CCL20, which are expressed by
Th17 cells, were increased. These ﬁndings imply involvement
of Th17 in liver GVHD [35]. PIF treatment prevented up-
regulation of these genes, indicating elimination of the
Th17 response in the liver of mice that underwent BMT.
iNOS-induced NO secretion is a major element in oxida-
tive stress-induced damage. Elimination of the marked
elevation in iNOS in GVHD liver by PIF treatment supports the
premise that PIF controls this critical pathway as well.
Signiﬁcantly, this protection was further conﬁrmed in both
liver and colon in the allogeneic BMT model, in which GVHD
is more severe. PIF also reduced iNOS expression, leading to
decreased NO secretion in cultured activated macrophages.
Figure 5. PIF protects against GVHD in the allogeneic BMT model. Mice underwent BMT with allogeneic bone marrow and spleen cells, and received PIF 1 mg/kg/day
or PBS via s.c.-implanted osmotic pumps for 2 weeks. (A) GVHD score at 4 weeks post-BMT; summary of 2 experiments. The difference between the PBS-treated
control mice and the PIF-treated group is signiﬁcant (P  . 01, t test). (B) Weight from day 0 to day 23 post-BMT. (C) Survival at 24 days post-BMT. Black indi-
cates % live mice; white, % of dead mice. (D) Colon GVHD. The upper panel summarizes the results of histological analysis of the colon at day 23 post-BMT (n ¼ 6/
group). The lower panel presents representative histology pictures of PIF- and PBS-treated allogeneic BMT recipient mice and healthy mice. (E) qPCR analysis of iNOS
mRNA expression in liver tissue (right) and in colon tissue (left) of PIF- and PBS-treated allogeneic BMT recipient mice and healthy mice. The between-group
differences in liver expression are signiﬁcant (PIF versus PBS, P  .05, Mann-Whitney U test).
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reduced NO toxicity associated with liver and colon GVHD.
Elevated iNOS expression in the GVHD liver has not been
reported previously, which is not surprising given the fact
that enhanced iNOS expression is closely related to the
severity of disease in patients with autoimmune hepatitis
[36] and inﬂammatory liver disease [37].
A role of NO in the intestinal pathology associated with
murine GVHD has been reported previously [38]. The
observation that PIF can decrease colon ulcers coupled with
decreased iNOS expression supports PIF-induced protection
of this target organ as well.
Taken together, our data imply that local regulation of
organ inﬂammation play a critical role in PIF-induced
protection. However, because in GVHD the inﬂammation is
equally systemic, we examined circulating cytokine levels aswell. PIF treatment reduced levels of circulating IL-17,
a cytokine expressed primarily by Th17 cells [4], but did
not affect IFN-g and the Th2 cytokine IL-4 levels. Th17 cells
direct the immune response against extracellular bacteria
and fungi, but also contribute to autoimmune diseases [4], as
well as GVHD [4,5,9,39]. The increased IL-17 levels in murine
GVHD serum and expression of Th17-related genes in the
liver indicate a Th17-type inﬂammatory response [5]. The
differences in IFN-g expression in the liver and circulation
might be related to differences in systemic effects versus
local effects. PIF locally eliminated liver inﬂammation, but
did not affect systemic INF-g, thereby enabling a maintained
Th1 response thatmay be associatedwith GVL. Together with
our in vitro results, these data suggest that PIF does not block
the immune response, but rather gently modiﬁes it by
directing APCs to amore regulatory phenotype. This idea is in
Figure 6. PIF has an immunomodulatory effect onmonocytes in vitro. (A) Results of a thymidine proliferation assay ofMLR using Balb/c and C57Blmouse splenocytes in
the presence of PIF. For negative control (Neg.), Balb/c mouse splenocytes were mixed with syngeneic irradiated splenocytes. One representative experiment is shown
out of 3 experiments performed. The differences among the positive control (Pos.), 150 nM PIF, and 200 nM PIF are signiﬁcant (*P .03, Mann-Whitney U test). (B) FACS
analysis of bone marrow cells (upper panel) and blood cells (lower panel) stained with FITC-PIF or FITC-PIFscr and antibodies against CD3 (T cell marker), CD19 (B cell
marker), and CD11b (marker formonocytes and granulocytes). The % of speciﬁc binding is the % of PIF-FITC binding cells minus the % of FITC-PIFscr (nonspeciﬁc) binding
cells. Data are a summary of 2 experiments. (C) Thymidine proliferation assay of mouse T cells cocultured with bone marrowederived monocytes; summary of 4
experiments. The monocytes were differentiated from bone marrow in the presence of 200 nM PIF, washed, and cocultured with T cells in the presence of anti-CD3
antibodies. The results are shown as % of control. The difference is highly signiﬁcant (**P  .001, Mann-Whitney U test). (D) qPCR analysis of iNOS mRNA expression
in RAW cells untreated or treated with PIF for 3 days and activated with LPS for 24 hours. Mouse HPRT-1 was used as a control gene. (E) NO secretion from RAW cells
untreated or treated with 200 nM PIF for the indicated times and activated with LPS for 24 hours. One representative experiment is shown out of 3 experiments
performed (*P< .05, **P< .05). (F) B7-H1 expression on bonemarrowederivedmonocytes, differentiatedwith GM-CSF in themedium for 10 days, in the presence of 200
nM PIF, by FACS analysis using anti-mouse B7-H1 antibodies. IFN-g was added in the last 24 hours of the culture. Data are a summary of 3 experiments (*P < .05).
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secreted PIF on the uterine milieu and systemic immunity
during pregnancy [21,22,24,25]. The reduction in IL-17 is also
compatible with the PIF effect observed in the chronic
experimental autoimmune encephalomyelitis model, in
which spinal cord inﬂammationwas reduced by inhibition of
such a critical pathway [26].
Given that the majority of patients undergoing BMT have
cancer, we examined whether PIF affects or interferes with
the beneﬁcial GVL effect. We report here that PIF does not
impair the GVL immune response. Further studies are
needed to examine this aspect of PIF-induced preserved GVL
effect with different leukemia models to further substantiate
this protective effect.Our group recently reported that PIF orchestrates
immune response in human immune cells [24,25]. The data
reported herein conﬁrm these observations, demonstrating
that monocytes are the main target of PIF. These cells are part
of the innate immunity ﬁrst line of defense; they also serve
as APCs, which direct the adaptive immune response.
Evidence of PIF-induced regulation of monocytes can be
characterized as follows: (1) PIF reduces allogeneic activation
in an MLR test; (2) PIF-treated monocytes reduce CD3-
activated T cell proliferation; (3) PIF increases expression of
the regulatory receptor B7H1 that binds CD28, a TCR cor-
eceptor, which is crucial for GVHD regulation after BMT [33];
and (4) PIF reduces LPS-induced iNOS expression and NO
secretion. Thus, the PIF-induced response can be exerted
Y. Azar et al. / Biol Blood Marrow Transplant 19 (2013) 519e528528through the regulation of APCs. Involvement of additional
mechanisms is currently under investigation.
In conclusion, our ﬁndings indicate that short-term,
low-dose synthetic PIF administration regulates the
immune response, thereby preventing deleterious acute
GVHD symptoms in the long term while preserving the
beneﬁcial GVL effect against cancer. The use of PIF in a clin-
ical setting is warranted and is currently in late-phase
planning.
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